Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
Merrill discusses the evolving non–muscle invasive bladder cancer treatment space.
Related Articles
MACE Risks Before and During Dialysis Initiation May Be Lower With ESA vs HIF-PHI
Anemia is prevalent among patient starting hemodialysis after end-stage kidney disease, and it is tied with major cardiovascular events.
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
Results from the phase 3 AMPLIFY trial are intended to support an application to the FDA for potential approval of 64Cu-SAR-bisPSMA.
Editorial Comment | Journal of Urology
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
Patient selection for cytoreductive nephrectomy in 2025
“Appropriate patient selection for CN is a highly individualized process that is improved with a multidisciplinary approach,” write the authors.
Complication Risks After BPH Surgery Vary by Patients’ CKD Stage, Surgery Type – Renal and Urology News
A study compared postoperative outcomes of laser surgery vs TURP for benign prostatic hyperplasia in patients with various stages of chronic kidney disease.
The Urology News Imaging Competition 2025
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Read our Cookies
Prostate cancer screening: Expert weighs in after Biden’s diagnosis
According to Adam B. Weiner, MD, a urologist at Cedars-Sinai Medical Center, men should begin prostate cancer screening around ages 50 to 55.
Artificial intelligence in bladder cancer diagnostics
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Read our Cookies
PSMA-PET Staging Tied to Lower BCR Risk After RP for Very High-Risk Prostate Cancer – Renal and Urology News
Investigators compared early oncologic outcomes by staging modality among men diagnosed with very high-risk prostate cancer.
DISCOVER THE IMPACT OF GEMTESA: A Selective β3-Adrenergic Agonist Now Approved for Effective OAB Treatment in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia (BPH)
Already Registered? Login here. REGISTER NOW Already registered?